Callio Therapeutics
Callio Therapeutics develops dual-payload antibody-drug conjugates (ADCs) for people with cancer, including patients with tumors that have developed resistance to existing therapies. Its platform pairs synergistic drug payloads and uses a proprietary linker to design targeted treatments intended to overcome resistance and deliver more durable responses.
Facts
- HQ
- Seattle, WA, USA
- Sectors
- Biotechnology Research
- Founded
- 2025
- Employees
- 24
- Stage
- Series A
Is this your organization? Claim it
Members see Callio Therapeutics's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
See all 8-
Jerome Boyd-Kirkup Co-Founder
-
Piers Ingram Co-Founder
-
Chris Hassig Executive, Chief Scientific Officer